TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
Biotec Betaglucans AS
Closing information (x1000 DKK)
Closing information | 2024/01 | 2023/01 | 2022/01 |
Turnover |
21,219
|
11,127
|
19,250 |
Financial expenses |
1,167
|
1,478
|
111 |
Earnings before taxes |
2,244
|
1,621
|
49,155 |
Total assets |
21,827
|
15,538
|
19,538 |
Current assets |
16,592
|
13,500
|
17,923 |
Current liabilities |
12,642
|
6,212
|
6,747 |
Equity capital |
9,186
|
9,326
|
12,791 |
- share capital |
657
|
687
|
743 |
Financial ratios
Fiscal year | 2024/01 | 2023/01 | 2022/01 |
Solvency |
42.1%
|
60.0%
|
65.5% |
Turnover per employee | |||
Profit as a percentage of turnover |
10.6%
|
14.6%
|
255.4% |
Return on assets (ROA) |
15.6%
|
19.9%
|
252.2% |
Current ratio |
131.2%
|
217.3%
|
265.6% |
Return on equity (ROE) |
24.4%
|
17.4%
|
384.3% |
Change turnover |
10,586
|
-6,674
|
-17,631 |
Change turnover % |
100%
|
-37%
|
-48% |
Chg. No. of employees | |||
Chg. No. of employees % |
Total value of public sale
Fiscal year | 2024/01 | 2023/01 | 2022/01 |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.